Pharmacoeconomics: theory and practice
№1, 2013, Vol.1

Kulikov A.Y., Litvinenko M.M., Yagudina R.I. 2497

In the first part of this publication, the methodology of analyzing the “cost of the disease”, the specifics of its calculation in the conditions of public health of the Russian Federation, various levels of research are considered in detail. The second part of the article is devoted to the presentation of the results of the first domestic study of the economic burden of multiple sclerosis, based on Russian data. The direct and indirect costs associated with multiple sclerosis were calculated. The results of the pharmacoeconomic analysis showed that the economic burden per patient per year depends on the form of the type of the underlying disease and amounts to 418,954 rubles for patients with a remitting type of flow, 556,150 rubles for patients with a returnable progressive type of flow with primary progressive course of multiple sclerosis. For the first time it has been shown that the ratio of direct and indirect costs for multiple sclerosis depends on the type of flow: with a remitting type of flow, direct costs prevail and they account for 65.7%, while for a backward-progressive and primary-progressive, a larger volume is occupied indirect costs, and they are 63.9% and 68.2%, respectively.